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Serotonin 5-HT 2A receptors (5-HT 2A Rs) have been implicated in schizophrenia. However, 
postmortem studies on 5-HT 2A Rs expression and functionality in schizophrenia are scarce. The 
5-HT 2A R mRNA and immunoreactive protein expression were evaluated in postmortem tissue 
from dorsolateral prefrontal cortex (DLPFC) of antipsychotic-free ( n = 18) and antipsychotic- 
treated ( n = 9) subjects with schizophrenia, and matched controls ( n = 27). Functional 
coupling of 5-HT 2A R to G-proteins was tested by measuring the activation induced by the 
agonist ( ±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (( ±)DOI) in antibody-capture 
[ 35 S]GTP γ S scintillation proximity assays (SPA). In antipsychotic-free schizophrenia subjects, 
5-HT 2A R mRNA expression and protein immunoreactivity in total homogenates was simi- 
lar to controls. In contrast, in antipsychotic-treated schizophrenia subjects, lower mRNA 
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expression (60 ±9% vs controls) and a trend to reduced protein immunoreactivity (86 ±5% vs 
antipsychotic-free subjects) just in membrane-enriched fractions was observed. [ 35 S]GTP γ S 
SPA revealed a significant ˜6% higher stimulation of G αi1 -protein by ( ±)DOI in schizophrenia, 
whereas activation of the canonical G αq/11 -protein pathway by ( ±)DOI remained unchanged. 
Expression of G αi1 - and G αq/11 -proteins did not differ between groups. Accordingly, in rats 
chronically treated with clozapine, but not with haloperidol, a 30–40% reduction was observed 
in 5-HT 2A R mRNA expression, 5-HT 2A R protein immunoreactivity and [ 3 H]ketanserin binding 
in brain cortical membranes. Overall, the data suggest a supersensitive 5-HT 2A R signaling 
through inhibitory G αi1 -proteins in schizophrenia. Together with previous results, a dysfunc- 
tional pro-hallucinogenic agonist-sensitive 5-HT 2A R conformation in postmortem DLPFC of 
subjects with schizophrenia is proposed. Atypical antipsychotic treatment would contribute to 
counterbalance this 5-HT 2A R supersensitivity by reducing receptor expression. 
© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC 





















































































Several findings support the involvement of the serotonin
5-HT 2A receptors (5-HT 2A Rs) in schizophrenia. Hallucino-
genic drugs, such as psilocybin or lysergic acid diethy-
lamide (LSD), trigger mental states resembling schizophre-
nia in healthy humans through the activation of 5-HT 2A Rs
( Carhart-Harris et al., 2016 ; Geyer and Vollenweider, 2008 ;
Nichols, 2016 ; Preller et al., 2018 ; Quednow et al., 2012 ;
Schmid et al., 2015 ), and worsen psychosis in schizophre-
nia patients ( Hoch et al., 1952 ). Most of the atypi-
cal antipsychotic drugs are characterized by high po-
tency as 5-HT 2A R antagonists ( Meltzer and Massey, 2011 ;
Miyamoto et al., 2012 ). 5-HT 2A R knockout (KO) mice
are insensitive to the behavioral effects of serotonergic
psychedelics ( González-Maeso et al., 2003 , 2007 ), and ge-
netic evidence links polymorphisms in the 5-HT 2A R ( HTR2A )
gene with sensorimotor gating deficits in schizophrenia
( Geyer and Vollenweider, 2008 ). Moreover, a differen-
tial epigenetic methylation of the HTR2A gene in the
brain of subjects with schizophrenia has been described
( Cheah et al., 2017 ; Abdolmaleky et al., 2011 ). In ad-
dition, studies in immunological, pharmacological, con-
genital and genetic rodent models of schizophrenia have
demonstrated increased 5-HT 2A R expression ( Dean et al.,
2008b ; Fomsgaard et al., 2018 ; Holloway et al., 2013 ;
Malkova et al., al.,2014 ; Moreno et al., 2011 ) and/or func-
tionality ( Holloway et al., 2013 ; Malkova et al., 2014 ;
Moreno et al., 2011 ; Santini et al., 2013 ). Together, these
findings suggest that up-regulation of cortical 5-HT 2A Rs
could predispose to psychosis in schizophrenia. 
The status of brain 5-HT 2A Rs in schizophrenia has been
mainly evaluated with radiotracers, both by in vivo neu-
roimaging and in vitro radioligand binding techniques, rais-
ing different outcomes. Thus, while some postmortem stud-
ies support increased 5-HT 2A R density, others observed no
changes and even decreases (see for reviews, Dean, 2003 ;
González-Maeso and Sealfon, 2009 ; Selvaraj et al., 2014 ).
These apparent discrepancies may depend on several con-
founding issues, such as the pharmacological properties
of the radioligands used to bind 5-HT 2A Rs, tissue prepa-
ration (total homogenates, membranes, cytosol, tissue
sections), discrimination between antipsychotic-free and
antipsychotic-treated subjects, the brain area selected, andother demographic and methodological variables (age, post-
mortem delay, gender, etc. ). Immunodetection is a feasible
method for in vitro postmortem studies of neurotransmit-
ter receptors. The use of antibodies to quantify receptor
protein expression minimizes concerns of pharmacological
selectivity associated with radioligands and avoids the in-
fluence of residual antipsychotic presence in samples com-
peting for the receptor. However, protein immunodetec-
tion fails to keep intact the ternary structure and does not
discriminate between molecular states of the receptor. In
this context, only one study of 5-HT 2A R immunoreactivity in
schizophrenia restricted to cerebellum evaluation has been
reported ( Eastwood et al., 2001 ). Similarly, studies with
positron emission tomography (PET) in living humans have
shown controversial results although the potential binding
seems to be reduced when selective 5-HT 2A R radiotracers as
[ 18 F]altanserin are used (see review in Selvaraj et al., 2014 ;
Erritzoe et al., 2008 ; Rasmussen et al., 2010 , 2016 ). 
The canonical 5-HT 2A R signaling pathway involves acti-
vation of G αq/11 -proteins that, subsequently, activate phos-
pholipase C, leading to inositol 1,4,5-triphosphate and 1,2-
diacylglycerol accumulation, releasing Ca + 2 from intracel-
lular stores and activating protein kinase C. In heterolo-
gous expression systems and rodents, non-hallucinogenic
LSD-analogous 5-HT 2A R agonists, such as lisuride, exclu-
sively activate G αq/11 -proteins, whereas hallucinogenic 5-
HT 2A R agonists, such as LSD and ( ±)DOI, engage signaling
through G αq/11 – but also through inhibitory G αi/o -proteins
( González-Maeso et al., 2007 ; Ibarra-Lecue et al., 2018 ;
Karaki et al., 2014 ). This differential activation is compat-
ible with the presence of a “functional selectivity” (also
known as “agonist-directed trafficking of receptor signal-
ing” or “biased agonism”) phenomenon in 5-HT 2A R activa-
tion ( Urban et al., 2007 ). Despite the extensive evaluation
of brain 5-HT 2A Rs density in schizophrenia, the status of
their functional coupling to G-proteins remains unknown.
Moreover, the hypothesis that a dysregulation of 5-HT 2A Rs
in schizophrenia could selectively affect the receptor cou-
pling to the hallucinogenic-mediated G αi/o -protein signaling
has not been investigated. 
The present study evaluated 5-HT 2A R mRNA and protein
expression in postmortem dorsolateral prefrontal cortex
(DLPFC) of subjects with schizophrenia and controls. A
strict treatment-controlled design was used to verify the


















































































































nfluence of antipsychotic drug treatment. Moreover, the 
xistence of dysfunctions in the coupling of 5-HT 2A R to dif-
erent G-protein-mediated pathways between schizophre- 
ia and control subjects was also tested. The DLPFC was 
elected as region of interest based on the described 
orphological alterations associated to schizophrenia 
 Jarskog et al., 2007 ; Lewis and González-Burgos, 2008 ) and
revious findings in PET studies ( Rasmussen et al., 2010 ,
016 ). 
. Experimental procedures 
.1. Human brain samples 
uman brains were obtained at autopsies in the Basque Institute
f Legal Medicine, Bilbao, Spain, in compliance with policies of
esearch and ethical boards for postmortem studies. Deaths were 
ubjected to retrospective searching for diagnosis and treatment 
sing examiner ś information and medical records. Twenty-seven 
ubjects with antemortem diagnosis of schizophrenia according to 
he Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, 
SM-IV-TR) were selected and matched to 27 control subjects 
ithout neuropsychiatric or drug abuse disorders. Individual 
atching was performed for age, gender and, as much as possible,
ostmortem delay (PMD). A toxicological screening performed at 
he National Institute of Toxicology, Madrid, Spain, allowed the 
lassification of subjects with schizophrenia as “antipsychotic- 
ree” (AP-free, n = 18) or “antipsychotic-treated” (AP-treated, 
 = 9) according to the absence or presence of antipsychotic drugs
n blood at the moment of death. It is noteworthy to remark that all
he current AP-free subjects had received antipsychotic prescrip- 
ion and should not be considered never-treated naïve subjects. 
pecimens of DLPFC were dissected following standard procedures 
 Rajkowska and Goldman-Rakic, 1995 ) and stored at −80 °C. A full
escription of the AP-free, AP-treated subjects, and respective 
ontrols with tissue integrity information (PMD, storage time, RNA 
ntegrity number, brain pH) is shown in Supplementary Table S1. 
.2. Animals and treatments 
ale Sprague-Dawley rats (220–320 g) were housed on a 12 h
ight/dark cycle at room temperature (22 °C) and 60% humidity with
ood and water available ad libitum . Animals were obtained and
ept at the Animal Facility SGIker of the University of the Basque
ountry. Animal care and experimental protocols were in accor- 
ance with European Union regulations and were approved by the
PV/EHU institutional Ethics Committee for animal welfare (CEEA). 
Rats were injected i.p., every 12 h, during 21 days, with saline
1 ml/kg, n = 10), haloperidol (0.5 mg/kg, n = 10) (Sigma Aldrich,
O, USA) or clozapine (5 mg/kg, n = 10) (Tocris, Bristol, UK).
aloperidol and clozapine were selected as representative drugs 
ith typical (selective affinity for dopamine D 2 receptor vs 5- 
T 2A R) or atypical (higher affinity for 5-HT 2A R than dopamine D 2 
eceptor family) antipsychotic profile, respectively. Animals were 
acrificed 48 h after the last injection of clozapine and 72 h after
he last injection of haloperidol or saline. Brains were removed and
he cortex was dissected and stored at −80 °C. 
.3. Quantitative real-time reverse transcription 
olymerase chain reaction 
ample preparation and procedures for determination of mRNA 
xpression of genes encoding 5-HT 2A ( HTR2A, Htr2a) and 5-HT 2C  HTR2C, Htr2c) receptors by quantitative real-time reverse tran-
cription polymerase chain reaction (qRT-PCR) were conducted by 
sing published procedures ( Muguruza et al., 2014 ). mRNA expres-
ion was normalized using the endogenous housekeeping genes
lyceraldehyde 3-phosphate dehydrogenase ( GAPDH ), beta-actin 
 ACTB ) and ribosomal protein S13 ( RPS13 ) for human samples, and
apdh, Actb and ribosomal protein S29 ( Rps29 ) for rat samples. A
egative internal control and a reference sample (pool of controls)
or each assay were included in all PCR plates. The assays iden-
ification numbers and conditions of the qRT-PCR are described in
upplementary Tables S2 and S3, respectively. Human samples were
lso assayed for RNA integrity number (RIN) using the Agilent 2100
ioanalyzer (Agilent Technologies) ( Stan et al., 2006 ). 
.4. Immunodetection 
estern blot experiments were performed in total homogenates
 García-Fuster et al., 2008 ), and in membrane-enriched (P 2 ) frac-
ions ( Muguruza et al., 2013 ) as previously described. The selected
rimary antibodies were rabbit polyclonal anti-5-HT 2A R (ab16028; 
:2000) from Abcam (Cambridge, UK), mouse monoclonal anti- 
-HT 2A R (sc-166775; 1:20,000), mouse monoclonal anti-G αi1 - (sc-
6536; 1:100) and rabbit polyclonal anti-G αq/11 -proteins (sc-392; 
:300) from Santa Cruz (CA, USA), and mouse monoclonal anti- β-
ctin (A1978; 1:200,000) from Sigma Aldrich, as loading control.
he fluorescent conjugated secondary antibodies Alexa Fluor TM 
80 goat anti-rabbit (A21076; 1:2500–1:8000) and Alexa Fluor TM 
80 goat anti-mouse (A21057; 1:8000) from Invitrogen (OR, USA),
nd IRDye TM 800 donkey anti-mouse (610-732-002; 1:10,000) and 
RDye TM 800 goat anti-rabbit (611-132-002; 1:5000) from Rockland 
mmunochemicals (PA, USA), were used to detect and quantify the
mmunoreactive signal by using the Odyssey Infrared Imaging Sys-
em (LI-COR Biosciences, NE, USA). All samples were analyzed at
east two times in different gels, obtaining a minimum of four mea-
urements for each sample. 
.5. Antibody-capture [ 35 S]GTP γS scintillation 
roximity assay (SPA) 
pecific activation of the different G α-proteins was determined by
sing a [ 35 S]GTP γ S binding assay followed by incubation with spe-
ific antibodies (see above) and SPA beads, as described ( Diez-
larcia et al., 2016 ; Erdozain et al., 2012 ). The 5-HT 2A/C R ago-
ist ( ±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (( ±)DOI) 
Sigma Aldrich) was used to stimulate [ 35 S]GTP γ S (1250 Ci/mmol)
Perkin Elmer Life Sciences, Maanstraat, Germany) binding at two
oncentrations close to those that elicit the 50% (EC 50 ≈300 nM) and
he maximal (10 μM) effects, estimated from concentration-effect
urves (data not shown). The 5-HT 2A R antagonist ketanserin (10 μM)
Tocris, UK) was used to determine the 5-HT 2A R specific component
f the stimulation induced by ( ±)DOI. Preliminary results demon-
trated that G αi1 displays, among the inhibitory G αi/o -proteins, the
ost efficient response of [ 35 S]GTP γ S binding stimulation by ( ±)DOI
 Miranda-Azpiazu et al., 2013 ). 
.6. Radioligand binding 
aturation binding assays (0.03–9 nM, ten concentrations) with 
 
3 H]ketanserin (specific activity 67 Ci/mmol; Perkin Elmer) in
at brain cortex membrane fractions were performed as de-
cribed ( Muguruza et al., 2013 , 2014 ). At this concentration range,
 
3 H]ketanserin exclusively binds 5-HT 2A Rs in rodent brain cortex
 Muguruza et al., 2013 ). 




































































































2.7. Data analysis and statistical procedures 
All studies were performed under a paired design where each
schizophrenia case and the respective matched control were
always processed simultaneously. The qRT-PCR data analysis was
performed by StepOne Software v2.1 (Applied Biosystems TM ). The
relative mRNA amount was calculated as 2 −Ct ±SEM – normalized
by both housekeeping genes and reference sample expression – and
data were standardized to control samples. In Western blot assays,
the immunoreactivity value of the target proteins was corrected
by the corresponding value of β-actin; and then, calculated as
percentage of a standard sample loaded in every single gel to
control for inter-assay variability. Finally, data were standardized
considering the mean value of the control samples as 100%. In
radioligand binding experiments, the apparent equilibrium disso-
ciation constant ( K D ) and the maximum density of specific binding
sites ( B max ) were obtained. Specific binding data obtained from
antibody-capture [ 35 S]GTP γ S SPA were transformed to percentage
of basal binding value (binding in the absence of any exogenous
drug) for each G α-protein subtype. 
Statistical comparisons were made by Student’s t -test and one-
way analysis of variance (ANOVA) followed by Dunnett’s post-hoc
test. Potential association of experimental results with age, PMD,
RIN, storage time and pH were tested. If significant correlation ex-
isted, the interaction was explored by analysis of covariance (AN-
COVA) where the group (schizophrenia or control) was the inde-
pendent variable, age, PMD, RIN, storage time or pH were the co-
variates, and the experimental result was the dependent variable.
Statistical comparisons of non-linear analyses in radioligand binding
assays were conducted by F -test. 
The analyses were carried out by using GraphPad Prism 5 TM and
InVivo Stat TM softwares. Values are shown as mean ±SEM. The level
of significance was chosen as p < 0.05. 
3. Results 
3.1. HTR2A mRNA expression and protein 
immunoreactivity in postmortem brain of subjects 
with schizophrenia and matched controls 
The mRNA expression of HTR2A showed no difference
between subjects with schizophrenia and controls ( Fig.
1 (a)). However, when subjects were grouped depending
on the absence/presence of antipsychotics in blood, lower
HTR2A mRNA expression was observed in AP-treated group
(60 ±9% % vs matched controls, p < 0.05), but not in AP-free
group (110 ±9% vs matched controls) ( Fig. 1 (a)). As HTR2A
mRNA expression showed significant correlation with the
RIN value ( r = 0.43, p < 0.01), results were reanalyzed by
ANCOVA with RIN as covariate. This analysis further con-
firmed the significant decrease of HTR2A mRNA expression
in AP-treated subjects ( F [1,15] = = 18.72, p < 0.05). The
mRNA expression of HTR2C was determined in parallel as
negative control. When compared to respective controls,
HTR2C mRNA expression was unaltered in both AP-free and
AP-treated subjects ( Fig. 1 (b)). 
In order to quantify the protein expression of 5-HT 2A R,
immunodetection with a specific antibody was performed.
Western blot assays showed a single band at ˜55 kDa (Sup-
plementary Fig. S1) whose specificity has previously been
demonstrated in 5-HT 2A R KO mice ( Fribourg et al., 2011 ).
The 5-HT 2A R protein immunoreactivity in total brain ho-
mogenates showed no significant alteration in schizophre-nia ( Fig. 1 (c)), even when subjects with schizophrenia were
separated in AP-free and AP-treated groups ( Fig. 1 (c)).
This lack of modulation contrasts with the elevated 5-
HT 2A R density previously observed by radioligand binding
assays in brain membrane fractions of AP-free subjects
( Muguruza et al., 2013 ). In order to check whether method-
ological issues could underlie this inconsistency (radioligand
binding vs immunodetection, and use of total homogenates
vs membrane-enriched fractions), new Western blot exper-
iments were performed in membrane preparations from
DLPFC of the same subjects. No clear differences were
observed in membrane 5-HT 2A R immunoreactivity between
schizophrenia and corresponding matched controls neither
in the AP-free group nor in the AP-treated group. However,
although not in statistically significant way, immunoreactive
signal of 5-HT 2A Rs in P 2 -membrane preparations was 17 ±6%
lower in AP-treated than in AP-free subjects ( Fig. 1 (d)). 
3.2. Functional coupling of 5-HT 2A Rs to 
G αq/11 - and G αi1 -proteins in postmortem brain of 
subjects with schizophrenia and matched controls 
Experiments of 5-HT 2A R agonist-mediated stimulation of
[ 35 S]GTP γ S binding to different G α-protein subtypes were
performed in DLPFC membranes to test the different 5-
HT 2A R signaling patterns. This approach informs about the
functional status of 5-HT 2A Rs in postmortem brain and al-
lows the evaluation of alterations in schizophrenia. 
The 5-HT 2A/C R agonist ( ±)DOI (300 nM and 10 μM) pro-
duced a selective activation of G αq/11 - and G αi1 -proteins
( Fig. 2 (a) and (b)) but not of G αi2, G αo and G αs subtypes (Sup-
plementary Fig. S2). The activation of these G α-proteins was
antagonized by the selective 5-HT 2A R antagonist ketanserin
(10 μM) ( Fig. 2 (a) and (b)). Moreover, the stimulation of
[ 35 S]GTP γ S binding by ( ±)DOI was absent in cortex of 5-
HT 2A R KO mice (Supplementary Fig. S3). ( ±)DOI stimulatory
effects did not correlate with any of the potential confound-
ing factors (age, PMD, RIN, storage time, pH and basal bind-
ing values). 
In membrane fractions, basal binding of [ 35 S]GTP γ S
to G αq/11 - and G αi1 -proteins, before ( ±)DOI stimulation,
was not different between schizophrenia subjects (45 ±4
fmol/ μg protein for G αq/11 ; 41 ±4 fmol/ μg protein for
G αi1 ) and controls (37 ±4 fmol/ μg protein for G αq/11 ; 38 ±3
fmol/ μg protein for G αi1 ). 
The stimulation of G αq/11 -protein induced by ( ±)DOI
showed no significant differences between schizophrenia
and control groups ( Fig. 2 (a)), even when considering the
presence of antipsychotic treatment. By contrast, G αi1 -
protein stimulation induced by ( ±)DOI at the two concen-
trations tested was significantly higher in the whole group
of schizophrenia (˜5–6% increase; p < 0.05) compared to
controls ( Fig. 2 (b)). This pattern of higher G αi1 -protein stim-
ulation was slightly more robust in AP-free subjects (˜6–
7% increase vs matched controls) than in AP-treated sub-
jects (˜5% increase vs matched controls). Therefore, the
canonical G αq/11 -protein pathway of 5-HT 2A Rs was unal-
tered whereas the “pro-hallucinogenic” G αi1 -protein path-
way was functionally overactive in DLPFC of subjects with
schizophrenia. 
5-HT 2A receptor in schizophrenia 1457 
Fig. 1 Relative expression levels of (a) HTR2A mRNA, (b) HTR2C mRNA, (c) 5-HT 2A R protein in total homogenates and (d) 5- 
HT 2A R protein in P 2 -membranes of DLPFC samples in the schizophrenia group (All), antipsychotic-free (AP-free) and antipsychotic- 
treated (AP-treated) subjects, and their respective matched controls (C). Inset (c) and (d): Representative images of 5-HT 2A R and 
β-actin (loading control) immunoreactivities in an AP-free, an AP-treated subjects, and in their respective controls. Bars represent 
















































increased in AP-free and returned to control values In order to test whether the supersensitivity of the ( ±)DOI
timulation of [ 35 S]GTP γ S binding may lay directly on 5-
T 2A Rs or on enhanced G αi1 -protein density, expression ex- 
eriments of G αq/11 - and G αi1 -protein subtypes were per-
ormed in membrane fractions of DLPFC samples from the 
ame subjects. No significant differences were observed be- 
ween schizophrenia and control groups in the immunore- 
ctivity neither of G αq/11 - (100 ±4% vs matched controls,
 > 0.05) nor of G αi1 -proteins (89 ±5% vs matched con-
rols, p > 0.05) ( Fig. 2 (c) and (d)), independently of the ab-
ence/presence of antipsychotic treatment ( Fig. 2 (c) and 
d)). 
.3. Effects of chronic treatment with 
ntipsychotics on Htr2a and Htr2c mRNA 
xpression, 5-HT 2A R immunoreactivity and 
 
3 H]ketanserin binding in rat brain cortex 
aking into account the results obtained in human DLPFC of
ubjects with schizophrenia, the effects of chronic (21 days) 
reatment with two different antipsychotic drugs (haloperi- 
ol and clozapine) on Htr2a and Htr2c mRNA expression and 
-HT 2A R protein immunoreactivity were tested in rat brain 
ortex. 
Htr2a mRNA expression was lower in rats after chronic 
reatment with the atypical antipsychotic clozapine (70 ±5% 
s saline, p < 0.01), but not with the typical antipsychoticaloperidol ( Fig. 3 (a)). In contrast, Htr2c mRNA expression
id not vary among the different groups ( Fig. 3 (b)). 
The 5-HT 2A R protein immunoreactivity in total ho- 
ogenates from rat cortex revealed no changes in the dif-
erent experimental groups ( Fig. 3 (c)). By contrast, in P 2 -
embrane preparations from the same animals, decreased 
-HT 2A R immunoreactivity was observed in clozapine- 
reated rats (63 ±6% vs saline, p < 0.01) with absence of
hanges in haloperidol-treated animals ( Fig. 3 (d)). 
In order to confirm the down-regulation observed in rat
rain cortical membranes by immunoblotting assays, satu- 
ation binding experiments with [ 3 H]ketanserin were per- 
ormed in the same membrane preparations. In this case, a
ignificant decrease of 5-HT 2A R density was also observed in
lozapine-treated ( B max 64 ±4% vs saline; p < 0.01) but not
n haloperidol-treated rats. No significant differences were 
bserved in K D values for any experimental group ( Fig. 3 (e);
able S4). 
. Discussion 
he present study shows that density of 5-HT 2A Rs in DLPFC
f subjects with schizophrenia is not altered when evalu-
ted by protein immunodetection. This finding apparently 
ontrasts with previous results in a similar population 
howing that [ 3 H]ketanserin binding to 5-HT 2A Rs was
1458 A. García-Bea, P. Miranda-Azpiazu and C. Muguruza et al. 
Fig. 2 ( ±)DOI (300 nM and 10 μM) induced stimulation of [ 35 S]GTP γ S binding to (a) G αq/11 - and (b) G αi1 -proteins in DLPFC of 
schizophrenia (white bars) and control (black bars) subjects, and reversion by the selective antagonist ketanserin (10 μM). Data 
are shown as percentage of basal [ 35 S]GTP γ S binding values for each G α-protein subtype. Graphic representation and represen- 
tative images of (c) G αq/11 - and (d) G αi1 -protein immunoreactivities in P 2 -membranes of DLPFC in the schizophrenia group (All), 
antipsychotic-free (AP-free) and antipsychotic-treated (AP-treated) subjects, and their respective matched controls (C). Bars rep- 



















































in AP-treated subjects ( Gonzalez-Maeso et al., 2008 ;
Muguruza et al., 2013 ). Likewise, evidence is provided that
mRNA expression of HTR2A is unaltered in DLPFC of AP-free
subjects. On the other hand, the study reports, for the
first time, that the hallucinogenic agonist ( ±)DOI displays a
supersensitive coupling of 5-HT 2A R to the G αi1 -protein path-
way in schizophrenia, while no alterations in the canonical
G αq/11 -protein pathway are detected. Altogether, the find-
ings in the present and previous studies ( Muguruza et al.,
2013 ) prompt the hypothesis of an enhanced proportion of
agonist-sensitive 5-HT 2A Rs in DLPFC of AP-free schizophre-
nia subjects. This increased 5-HT 2A R sensitivity would not
be the consequence of increased receptor synthesis and
expression, but seems to represent an altered conforma-
tional exchange between G-protein-coupled (active) and
G-protein-uncoupled receptor states ( Muguruza et al.,
2013 ). The equilibrium displacement towards the agonist-
sensitive active conformation of the 5-HT 2A R constitutes the
signal-driving stimulus that is experimentally observed as an
increased coupling activity to G-proteins in schizophrenia.
This 5-HT 2A R supersensitivity occurs without changes in
basal [ 35 S]GTP γ S binding values or G α-protein immunoreac-
tive levels, which discards a primary alteration of G-protein
density. Whether this trend to 5-HT 2A Rs hyperactivity
represents an intrinsic constitutive dysfunction of thereceptor or is a consequence of abnormalities in associated
proteins ( Dean et al., 2008a ; Roth, 2011 ) deserves further
investigation. 
Despite the multiple mRNA expression and radioligand
binding studies performed in postmortem brain, a definitive
understanding of 5-HT 2A R status in schizophrenia, especially
in the absence of antipsychotic treatment, remains uncer-
tain. Thus, postmortem radioligand binding assays have
found decreased, unchanged and increased brain 5-HT 2A R
density in schizophrenia (see for references, Dean, 2003 ;
González-Maeso and Sealfon, 2009 ). In vivo PET neuroimag-
ing studies have mainly proposed a reduction of the 5-HT 2A R
binding potential in AP-free patients (see for references,
Selvaraj et al., 2014 ; Rasmussen et al., 2010 , 2016 ). As
already mentioned, these apparent discrepancies might be
related to the different pharmacological profile of the radi-
olabeled drugs used as radiotracers. Thus, it seems that the
population of 5-HT 2A Rs with high-affinity for agonists, that
represents the active receptor conformational state, would
be increased in schizophrenia whereas the total 5-HT 2A R
protein density would remain unchanged. Consequently,
the population of 5-HT 2A Rs with high-affinity for inverse
agonists, which represents the uncoupled receptor confor-
mational state, should be decreased in AP-free subjects.
Indirect data obtained in studies with postmortem DLPFC
5-HT 2A receptor in schizophrenia 1459 
Fig. 3 Relative expression levels of ( a ) Htr2a mRNA, (b) Htr2c mRNA, (c) 5-HT 2A R protein in total homogenates,(d) 5-HT 2A R protein 
in P 2 -membranes, and (e) specific [ 3 H]ketanserin binding saturation curves (0.03–9 nM) in P 2 -membranes from brain cortex of rats 
chronically treated with saline (SAL), haloperidol (HAL), or clozapine (CLZ). Inset (c) and (d): Representative images of 5-HT 2A R and 
β-actin (loading control) immunoreactivities for each group. Bars and points represent mean ±SEM values of 10 animals. ∗∗p < 0.01 vs 
saline (one-way ANOVA followed by Dunnett ś post-hoc test). In (e), Bmax differences between saline- and clozapine-treated rats 





















p  issue suggest that the PET radioligand most commonly 
sed to identify 5-HT2ARs receptors, altanserin, acts as 
n inverse agonist and shows responses compatible with 
he documented reduction of [ 18 F]altanserin binding de- 
cribed in PET studies of schizophrenia ( Muguruza et al.,
013 ). Indeed, the interest in the design and further
se of 5-HT 2A Rs agonist radioligands for PET studies in 
chizophrenia has been recognized ( L’Estrade et al., 
018 ). 
Apart from selection of suitable immunological or radi- 
ligand tools for identification of 5-HT 2A Rs, confounding ariables such as age, sex, PMD, and pharmacological treat-
ent could also underlie the observed differences between 
ostmortem evaluations of this receptor in schizophrenia. 
n the present work, subjects were individually matched in
 way that significant differences for confounding factors 
etween schizophrenia and control subjects were absent. 
t is worth mentioning that twenty-one of the 27 subjects
ith schizophrenia had died by suicide. Although suicide 
as been proposed as a confounding factor in evaluation of
-HT 2A Rs ( Underwood et al., 2018 and references therein),
revious data in frontal cortex of suicide victims with


























































































































a variety of psychiatric disorders (see for references,
Muguruza et al., 2013 , 2014 ; Zhao et al., 2015 ) and a
recent meta-analysis have argued that suicide unlikely
represents a major confounder in 5-HT 2A R binding studies
( Selvaraj et al., 2014 ). 
The presence of antipsychotic treatment in schizophrenia
is an essential confounding factor to be considered. Second
generation antipsychotics induce changes in 5-HT 2A Rs de-
tection through modulation of their expression as demon-
strated in animal models ( González-Maeso et al., 2008 ;
Kurita et al., 2012 ; Yadav et al., 2011 ), or by blockade
of the radioligand binding site due to residual presence of
antipsychotics acting as 5-HT 2A R antagonists ( Dean et al.,
2008a ). Interestingly, most of the studies suggesting de-
creased or unchanged [ 3 H]ketanserin binding in schizophre-
nia have been performed in brain of AP-treated subjects
(see for references, Muguruza et al., 2013 ). Therefore, in
order to discard eventual influences of antipsychotics in
postmortem studies, independent and well-matched groups
of AP-free and AP-treated subjects should be selected and
independently analyzed. The influence of residual pres-
ence of antipsychotics competing for the radioligand bind-
ing pocket can also be overcome by using immunodetec-
tion of the 5-HT 2A R protein with selective antibodies as
alternative methodology. In the present study, the im-
munoreactive expression of 5-HT 2A R protein is not mod-
ified in DLPFC homogenates of AP-treated subjects with
schizophrenia. A similar pattern has been found in cere-
bellum cytosolic fractions of AP-treated schizophrenia sub-
jects ( Eastwood et al., 2001 ). Reevaluation of 5-HT 2A R pro-
tein expression in membrane-enriched fractions of the same
subjects indicates a trend towards a reduction, associ-
ated to antipsychotic treatment, suggesting that this down-
regulation mainly affect the 5-HT 2A R fraction expressed in
plasma membranes. This membrane P 2 fraction represents
the population able to interact with G-proteins and sensitive
to agonist interaction. Moreover, the analysis of HTR2A gene
expression clearly confirms a reduction of HTR2A mRNA in
AP-treated that was not present in AP-free subjects. This
finding is consistent with previous postmortem studies per-
formed in AP-treated populations that proposed decreased
HTR2A mRNA levels in schizophrenia ( Burnet et al., 1996 ;
Hernandez and Sokolov, 2000 ; López-Figueroa et al., 2004 ).
In order to confirm these effects of antipsychotic treatment
on mRNA and protein expression, long-term administration
of haloperidol and clozapine, which display low and high
affinity for 5-HT 2A R, respectively, was performed in rats.
The results show a reduction in Htr2a gene expression and
in 5-HT 2A R protein immunoreactivity in membrane-enriched
preparations induced by clozapine but not by haloperidol
treatment. In contrast, no changes in 5-HT 2A R protein im-
munodetection in cortical total homogenates are observed.
Moreover, radioligand binding assays in membrane fractions
of the same animals demonstrate that chronic clozapine de-
creases [ 3 H]ketanserin binding, which mimics previous re-
sults in DLPFC from AP-treated subjects ( Muguruza et al.,
2013 ). All these findings make the overactive G αi1 -protein
stimulation by ( ±)DOI an improbable consequence of long-
term exposition of both AP-free and AP-treated subjects to
antipsychotic drugs and point to an intrinsic alteration in
schizophrenia. Globally considered, the present and previ-
ous data indicate that up-regulation of the agonist-sensitivefunctional 5-HT 2A R conformation in schizophrenia before
treatment is counterbalanced through a decreased recep-
tor synthesis and cell membrane protein expression in-
duced by atypical antipsychotics. The expression of 5-HT 2A R
in the cytosolic fraction of human brain homogenates is
higher than in plasma membranes, a fact that induces
greater experimental variability ( Eastwood et al., 2001 ).
However, although representing the minor population, 5-
HT 2A R membrane fraction probably represents the popula-
tion accessible to the neurotransmitter and, consequently,
the most sensitive for functional coupling to G-proteins
following interaction with agonists ( Bhatnagar et al.,
2001 ). The relevance that this reversion mechanism of
the enhanced 5-HT 2A R function in schizophrenia plays
on the therapeutic activity of atypical antipsychotics is
unknown. 
The present results provide evidence of a 5-HT 2A Rs cou-
pling to different G α-proteins in human DLPFC membranes
when stimulated by the agonist ( ±)DOI, in concordance with
the existence of functional selectivity or biased agonism
through this receptor. In animals, activation of inhibitory
G αi/o -proteins by ( ±)DOI and other LSD-like agonist drugs is
considered a fingerprint of hallucinogenic properties medi-
ated by 5-HT 2A Rs ( González-Maeso et al., 2007 ). The en-
hanced ( ±)DOI-mediated 5-HT 2A R stimulation by ( ±)DOI in
schizophrenia involves signaling through inhibitory G αi1 - but
not G αq/11 -proteins, indicating that the functional hyperac-
tivity of 5-HT 2A Rs is selectively exerted on hallucinogenic
signal transduction pathways of this receptor. Whether
other non-canonical 5-HT 2A R pathways involving G-protein
dependent and independent pathways ( Roth, 2011 ) are also
altered in schizophrenia remains to be studied. The drug
( ±)DOI represents a 5-HT 2A/C R agonist ( Knight et al., 2004 )
that promotes psychotic-like behaviors through 5-HT 2A Rs
( González-Maeso et al., 2003 ; Halberstadt and Geyer, 2013 ;
Moreno et al., 2013 ) and disorganizes electrophysiological
network activity of prefrontal cortex ( Celada et al., 2008 ).
The blockade of ( ±)DOI stimulation by the selective 5-
HT 2A R antagonist ketanserin ( Knight et al., 2004 ) and the
absence of this stimulation in 5-HT 2A R KO mice discard the
implication of 5-HT 2C Rs in the observed effects of ( ±)DOI.
The apparent scarce 5–7% increase of G αi1 -protein activa-
tion by 5-HT 2A Rs in schizophrenia is not particularly sur-
prising, since functional response in [ 35 S]GTP γ S binding as-
says are known to be highly dependent on experimental
conditions to detect GDP/GTP exchange. Along the same
line, the possibility that this limited increase of G αi1 -protein
stimulation by ( ±)DOI could represent a selective dysfunc-
tion of some DLPFC neuron subtypes, generating a dilution
effect, is an alternative explanation that deserves further
investigation. 
In conclusion, an overactive 5-HT 2A R signal trafficking
through G αi1 -proteins in DLPFC of subjects with schizophre-
nia that would predispose to psychotic symptoms has been
found. In this context, schizophrenic patients and relatives
have been described as more susceptible to psychotic re-
sponses induced by the hallucinogenic 5-HT 2A R agonist LSD
( Anastasopoulos and Photiades, 1962 ; Hoch et al., 1952 ).
Based on the present findings, it is tempting to specu-
late that drugs with 5-HT 2A R functional selective properties
as antagonists or inverse agonists in G αi1 -protein signaling
pathways could represent better pharmacological tools for
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